Home>>Signaling Pathways>> Microbiology & Virology>> RSV>>Lumicitabine (ALS-008176)

Lumicitabine (ALS-008176) (Synonyms: ALS-008176; ALS-8176)

Catalog No.GC32087

Lumicitabine (ALS-008176) (ALS-008176) is an inhibitor of the respiratory syncytial virus (RSV) polymerase.

Products are for research use only. Not for human use. We do not sell to patients.

Lumicitabine (ALS-008176) Chemical Structure

Cas No.: 1445385-02-3

Size Price Stock Qty
10mM (in 1mL DMSO)
$307.00
In stock
1mg
$138.00
In stock
5mg
$321.00
In stock
10mg
$459.00
In stock
50mg
$1,379.00
In stock
100mg
$1,930.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Lumicitabine (ALS-008176) is an inhibitor of the respiratory syncytial virus (RSV) polymerase.

Lumicitabine is an orally bioavailable prodrug of the novel RSV replication inhibitor ALS-008112, a cytidine nucleoside analogue[1].

Lumicitabine demonstrates excellent anti-RSV efficacy and safety in a phase 2 clinical RSV challenge study. It exhibits good oral bioavailability and a high level of 2c-TP in vivo. Lumicitabine has excellent stability profiles in formulations (>24 h storage stability in 0.5% methylcellulose aqueous formulation at rt) and simulats gastric and intestinal fluids (half-life >2 h). Its solubility is adequate to support oral administration in solutions with relatively low percentage of organic solvent and in aqueous suspensions. High levels of NMP and NTP are obtained following oral administration of Lumicitabine to monkeys[2]. In an adult human challenge study, Lumicitabine has shown efficacy against RSV infection[1].

[1]. DeVincenzo JP, et al. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. N Engl J Med. 2015 Nov 19;373(21):2048-58. [2]. Wang G, et al. Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem. 2015 Feb 26;58(4):1862-78.

Reviews

Review for Lumicitabine (ALS-008176)

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Lumicitabine (ALS-008176)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.